The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smyth, M. J.
Right arrow Articles by Hayakawa, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smyth, M. J.
Right arrow Articles by Hayakawa, Y.
The Journal of Immunology, 2006, 176: 1582-1587.
Copyright © 2006 by The American Association of Immunologists

CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer1

Mark J. Smyth2,*, Michele W. L. Teng*, Jeremy Swann*, Konstantinos Kyparissoudis{dagger}, Dale I. Godfrey{dagger} and Yoshihiro Hayakawa*

* Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia; and {dagger} Department of Microbiology and Immunology, University of Melbourne, Parkville, Australia

CD4+CD25+ regulatory T cells (Treg) that suppress T cell-mediated immune responses may also regulate other arms of an effective immune response. In particular, in this study we show that Treg directly inhibit NKG2D-mediated NK cell cytotoxicity in vitro and in vivo, effectively suppressing NK cell-mediated tumor rejection. In vitro, Treg were shown to inhibit NKG2D-mediated cytolysis largely by a TGF-beta-dependent mechanism and independently of IL-10. Adoptively transferred Treg suppressed NK cell antimetastatic function in RAG-1-deficient mice. Depletion of Treg before NK cell activation via NKG2D and the activating IL-12 cytokine, dramatically enhanced NK cell-mediated suppression of tumor growth and metastases. Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. Fujita, K. Teramoto, Y. Ozaki, J. Hanaoka, N. Tezuka, Y. Itoh, T. Asai, S. Fujino, K. Kontani, and K. Ogasawara
Inhibition of Transforming Growth Factor-{beta}-Mediated Immunosuppression in Tumor-Draining Lymph Nodes Augments Antitumor Responses by Various Immunologic Cell Types
Cancer Res., June 15, 2009; 69(12): 5142 - 5150.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Lundqvist, H. Yokoyama, A. Smith, M. Berg, and R. Childs
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
Blood, June 11, 2009; 113(24): 6120 - 6127.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y.-O. Ahn, J.-C. Lee, M.-W. Sung, and D. S. Heo
Presence of Membrane-Bound TGF-{beta}1 and Its Regulation by IL-2-Activated Immune Cell-Derived IFN-{gamma} in Head and Neck Squamous Cell Carcinoma Cell Lines
J. Immunol., May 15, 2009; 182(10): 6114 - 6120.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Michaeli, G. Denkberg, K. Sinik, L. Lantzy, C. Chih-Sheng, C. Beauverd, T. Ziv, P. Romero, and Y. Reiter
Expression Hierarchy of T Cell Epitopes from Melanoma Differentiation Antigens: Unexpected High Level Presentation of Tyrosinase-HLA-A2 Complexes Revealed by Peptide-Specific, MHC-Restricted, TCR-Like Antibodies
J. Immunol., May 15, 2009; 182(10): 6328 - 6341.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. W. Mailloux and M. R. I. Young
NK-Dependent Increases in CCL22 Secretion Selectively Recruits Regulatory T Cells to the Tumor Microenvironment
J. Immunol., March 1, 2009; 182(5): 2753 - 2765.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
J. HIGASHIJIMA, M. SHIMADA, M. CHIKAKIYO, T. MIYATANI, K. YOSHIKAWA, M. NISHIOKA, T. IWATA, and N. KURITA
Effect of Splenectomy on Antitumor Immune System in Mice
Anticancer Res, January 1, 2009; 29(1): 385 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Bos, S. van Duikeren, H. Morreau, K. Franken, T. N.M. Schumacher, J. B. Haanen, S. H. van der Burg, C. J.M. Melief, and R. Offringa
Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell-Mediated Targeting of Carcinoembryonic Antigen
Cancer Res., October 15, 2008; 68(20): 8446 - 8455.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. J. Pegram, J. T. Jackson, M. J. Smyth, M. H. Kershaw, and P. K. Darcy
Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo
J. Immunol., September 1, 2008; 181(5): 3449 - 3455.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Mignot, E. Ullrich, M. Bonmort, C. Menard, L. Apetoh, J. Taieb, D. Bosisio, S. Sozzani, M. Ferrantini, J. Schmitz, et al.
The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2
J. Immunol., May 15, 2008; 180(10): 6477 - 6483.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Terme, N. Chaput, B. Combadiere, A. Ma, T. Ohteki, and L. Zitvogel
Regulatory T Cells Control Dendritic Cell/NK Cell Cross-Talk in Lymph Nodes at the Steady State by Inhibiting CD4+ Self-Reactive T Cells
J. Immunol., April 1, 2008; 180(7): 4679 - 4686.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Roy, P. F. Barnes, A. Garg, S. Wu, D. Cosman, and R. Vankayalapati
NK Cells Lyse T Regulatory Cells That Expand in Response to an Intracellular Pathogen
J. Immunol., February 1, 2008; 180(3): 1729 - 1736.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. G. Elpek, E. S. Yolcu, D. D. H. Franke, C. Lacelle, R.-H. Schabowsky, and H. Shirwan
Ex Vivo Expansion of CD4+CD25+FoxP3+ T Regulatory Cells Based on Synergy between IL-2 and 4-1BB Signaling
J. Immunol., December 1, 2007; 179(11): 7295 - 7304.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Zhou, L. L'italien, D. Hodges, and X. M. Schebye
Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors
J. Immunol., December 1, 2007; 179(11): 7365 - 7375.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Yano, T. Ishida, A. Inagaki, T. Ishii, J. Ding, S. Kusumoto, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda
Defucosylated Anti CC Chemokine Receptor 4 Monoclonal Antibody Combined with Immunomodulatory Cytokines: A Novel Immunotherapy for Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
Clin. Cancer Res., November 1, 2007; 13(21): 6494 - 6500.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. M. Whitmore, A. Iparraguirre, L. Kubelka, W. Weninger, T. Hai, and B. R. G. Williams
Negative Regulation of TLR-Signaling Pathways by Activating Transcription Factor-3
J. Immunol., September 15, 2007; 179(6): 3622 - 3630.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Hyka-Nouspikel, L. Lucian, E. Murphy, T. McClanahan, and J. H. Phillips
DAP10 Deficiency Breaks the Immune Tolerance against Transplantable Syngeneic Melanoma
J. Immunol., September 15, 2007; 179(6): 3763 - 3771.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. E.A. Street, N. Zerafa, M. Iezzi, J. A. Westwood, J. Stagg, P. Musiani, and M. J. Smyth
Host Perforin Reduces Tumor Number but Does Not Increase Survival in Oncogene-Driven Mammary Adenocarcinoma
Cancer Res., June 1, 2007; 67(11): 5454 - 5460.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Zamai, C. Ponti, P. Mirandola, G. Gobbi, S. Papa, L. Galeotti, L. Cocco, and M. Vitale
NK Cells and Cancer
J. Immunol., April 1, 2007; 178(7): 4011 - 4016.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Rudge, S. P. Barrett, B. Scott, and I. R. van Driel
Infiltration of a Mesothelioma by IFN-{gamma}-Producing Cells and Tumor Rejection after Depletion of Regulatory T Cells
J. Immunol., April 1, 2007; 178(7): 4089 - 4096.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
G. Yang, A. Liu, Q. Xie, T. B. Guo, B. Wan, B. Zhou, and J. Z. Zhang
Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B
Int. Immunol., February 1, 2007; 19(2): 133 - 140.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
N. Ralainirina, A. Poli, T. Michel, L. Poos, E. Andres, F. Hentges, and J. Zimmer
Control of NK cell functions by CD4+CD25+ regulatory T cells
J. Leukoc. Biol., January 1, 2007; 81(1): 144 - 153.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Bui, R. Uppaluri, C.-S. Hsieh, and R. D. Schreiber
Comparative Analysis of Regulatory and Effector T Cells in Progressively Growing versus Rejecting Tumors of Similar Origins.
Cancer Res., July 15, 2006; 66(14): 7301 - 7309.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
K. Wing, Z. Fehervari, and S. Sakaguchi
Emerging possibilities in the development and function of regulatory T cells
Int. Immunol., July 1, 2006; 18(7): 991 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. Barao, A. M. Hanash, W. Hallett, L. A. Welniak, K. Sun, D. Redelman, B. R. Blazar, R. B. Levy, and W. J. Murphy
Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells
PNAS, April 4, 2006; 103(14): 5460 - 5465.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.